If you couldn’t join us for the DealBook Debrief call with Tom Friedman yesterday, the highlights are at the bottom of the email and the full recording is here. Skip to 9:00 to hear Tom sing a gospel song — we covered a lot of ground in the call. (Want this in your inbox each morning? Sign up here.)

The policies — and pharmaceuticals — that could help reopen the economy

The markets are abuzz about promising early data from a clinical trial of Gilead’s antiviral drug remdesivir on coronavirus patients. It comes as President Trump unveiled guidelines for restarting the U.S. economy yesterday, but acknowledged that it would be up to individual states to decide when to reopen for business.

Gilead’s shares are soaring in after-hours trading after STAT reported that patients appeared to show rapid recovery after taking remdesivir, suggesting that it could reduce the deadliness of Covid-19, and potentially make reopening the economy less risky.

• But experts caution that clinical trials for all such treatments are continuing and will take a long time to play out. Gilead itself warned that more data was needed to determine the drug’s efficacy.